title: Abacavir/lamivudine + unboosted atazanavir in routine clinical practice: Twelve years experience.
abstract: To describe the experience using the combination abacavir, lamivudine plus non-boosted atazanavir (ABC/3TC+ATV) in a group of pretreated patients.
  
  
  
  We performed a retrospective observational study to describe baseline characteristics and the evolution of patients who had received or were treating with ABC/3TC+ATV, from November 2004 and June 15th 2015, in the clinical setting.
  
  
  
  Overall, 236 patients were included in the study. Median age (IQR) was 45 (42-50) years and 69% were male. The main reasons for using this combination were previous toxicity in 130 patients (56%), simplification in 60 (20%) and virologic failure in 29 (14%). Previous treatment was based in boosted protease inhibitor in 115 patients (48.7%), 3 analogs in 56 (28%) and non-analogous based in 19 (8.1%). Median treatment length was 2.2 years (IQR0.8-5.3). A total of 66 (28%) patients continue receiving ABC/3TC+ATV (median time 5.7, IQR2.2-8.3), treatment was changed in 170 patients (72%) (median time 1.6 years, IQR0.7-3.6), and 22 (9.3%) patients were lost. Virological failure was assessed in 30 patients.
  
  
  
  In selected patients, ABC/3TC+ATV is a durable and attractive therapeutic alternative.
authors.affiliation: Servicio de Medicina Interna-Unidad de VIH, Hospital Universitario La Paz, Madrid, España. Electronic address: eulalia.valencia@salud.madrid.org.
authors.forename: M Eulalia
authors.initials: ME
authors.lastname: Valencia
authors.affiliation: Servicio de Medicina Interna-Unidad de VIH, Hospital Universitario La Paz, Madrid, España.
authors.forename: Luz
authors.initials: L
authors.lastname: Martín-Carbonero
authors.affiliation: Servicio de Medicina Interna-Unidad de VIH, Hospital Universitario La Paz, Madrid, España.
authors.forename: Victoria
authors.initials: V
authors.lastname: Moreno
authors.affiliation: Servicio de Medicina Interna-Unidad de VIH, Hospital Universitario La Paz, Madrid, España.
authors.forename: José Ignacio
authors.initials: JI
authors.lastname: Bernardino
authors.affiliation: Servicio de Medicina Interna-Unidad de VIH, Hospital Universitario La Paz, Madrid, España.
authors.forename: M Luisa
authors.initials: ML
authors.lastname: Montes
authors.affiliation: Servicio de Medicina Interna-Unidad de VIH, Hospital Universitario La Paz, Madrid, España.
authors.forename: Rocío
authors.initials: R
authors.lastname: Montejano
mesh_terms: D000328:Adult; D000069446:Atazanavir Sulfate / Q000008:administration & dosage*; D015224:Dideoxynucleosides / Q000008:administration & dosage*; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013997:Time Factors; D000099227:Abacavir
chemical_list: D000069446:Atazanavir Sulfate; D015224:Dideoxynucleosides; D004338:Drug Combinations; D017320:HIV Protease Inhibitors; D019259:Lamivudine; C492871:abacavir, lamivudine drug combination; D000099227:Abacavir
keywords: Abacavir/lamivudina + atazanavir; Abacavir/lamivudine + atazanavir; Atazanavir en práctica clínica diaria; Atazanavir in routine clinical practice; Atazanavir sin potenciar; Unboosted atazanavir